Literature DB >> 24021287

A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis.

Kathleen Machiels1, Marie Joossens2, João Sabino1, Vicky De Preter3, Ingrid Arijs1, Venessa Eeckhaut4, Vera Ballet1, Karolien Claes1, Filip Van Immerseel4, Kristin Verbeke3, Marc Ferrante1, Jan Verhaegen5, Paul Rutgeerts1, Séverine Vermeire1.   

Abstract

OBJECTIVE: Bacteria play an important role in the onset and perpetuation of intestinal inflammation in inflammatory bowel disease (IBD). Unlike in Crohn's disease (CD), in which dysbiosis has been better characterised, in ulcerative colitis (UC), only small cohorts have been studied and showed conflicting data. Therefore, we evaluated in a large cohort if the microbial signature described in CD is also present in UC, and if we could characterise predominant dysbiosis in UC. To assess the functional impact of dysbiosis, we quantified the bacterial metabolites.
DESIGN: The predominant microbiota from 127 UC patients and 87 age and sex-matched controls was analysed using denaturing gradient gel electrophoresis (DGGE) analysis. Differences were quantitatively validated using real-time PCR. Metabolites were quantified using gas chromatography-mass spectrometry.
RESULTS: Based on DGGE analysis, the microbial signature previously described in CD was not present in UC. Real-time PCR analysis revealed a lower abundance of Roseburia hominis (p<0.0001) and Faecalibacterium prausnitzii (p<0.0001) in UC patients compared to controls. Both species showed an inverse correlation with disease activity. Short-chain fatty acids (SCFA) were reduced in UC patients (p=0.014), but no direct correlation between SCFA and the identified bacteria was found.
CONCLUSIONS: The composition of the fecal microbiota of UC patients differs from that of healthy individuals: we found a reduction in R hominis and F prausnitzii, both well-known butyrate-producing bacteria of the Firmicutes phylum. These results underscore the importance of dysbiosis in IBD but suggest that different bacterial species contribute to the pathogenesis of UC and CD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  INTESTINAL BACTERIA; ULCERATIVE COLITIS

Mesh:

Substances:

Year:  2013        PMID: 24021287     DOI: 10.1136/gutjnl-2013-304833

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  506 in total

1.  Editorial on "Cancer and the microbiota" published in Science.

Authors:  Alison K Hamm; Tiffany L Weir
Journal:  Ann Transl Med       Date:  2015-08

2.  Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease.

Authors:  Mireia Lopez-Siles; Margarita Martinez-Medina; Carles Abellà; David Busquets; Miriam Sabat-Mir; Sylvia H Duncan; Xavier Aldeguer; Harry J Flint; L Jesús Garcia-Gil
Journal:  Appl Environ Microbiol       Date:  2015-08-21       Impact factor: 4.792

Review 3.  The role of the gut microbiome in systemic inflammatory disease.

Authors:  Jose C Clemente; Julia Manasson; Jose U Scher
Journal:  BMJ       Date:  2018-01-08

4.  Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels.

Authors:  Rosica Valcheva; Petya Koleva; Inés Martínez; Jens Walter; Michael G Gänzle; Levinus A Dieleman
Journal:  Gut Microbes       Date:  2018-11-05

5.  The commensal microbiota exacerbate infectious colitis in stressor-exposed mice.

Authors:  Jeffrey D Galley; Nicola M Parry; Brian M M Ahmer; James G Fox; Michael T Bailey
Journal:  Brain Behav Immun       Date:  2016-09-12       Impact factor: 7.217

Review 6.  The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications.

Authors:  Jason R Goldsmith; R Balfour Sartor
Journal:  J Gastroenterol       Date:  2014-03-21       Impact factor: 7.527

7.  Metabolic alterations to the mucosal microbiota in inflammatory bowel disease.

Authors:  Michael Davenport; Jordan Poles; Jacqueline M Leung; Martin J Wolff; Wasif M Abidi; Thomas Ullman; Lloyd Mayer; Ilseung Cho; P'ng Loke
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

8.  PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis.

Authors:  M R Spalinger; S Kasper; C Chassard; T Raselli; I Frey-Wagner; C Gottier; S Lang; K Atrott; S R Vavricka; F Mair; B Becher; C Lacroix; M Fried; G Rogler; M Scharl
Journal:  Mucosal Immunol       Date:  2014-12-10       Impact factor: 7.313

9.  Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment.

Authors:  Nai-Lun Yeh; Che-Yuan Hsu; Tsen-Fang Tsai; Hsien-Yi Chiu
Journal:  Clin Drug Investig       Date:  2019-12       Impact factor: 2.859

Review 10.  Hypoxia and Mucosal Inflammation.

Authors:  Sean P Colgan; Eric L Campbell; Douglas J Kominsky
Journal:  Annu Rev Pathol       Date:  2016-05-23       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.